{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:51:13Z","timestamp":1789613473925,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T00:00:00Z","timestamp":1267574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11095-009-0031-z","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T20:19:02Z","timestamp":1267561142000},"page":"735-738","source":"Crossref","is-referenced-by-count":102,"title":["Drug Delivery Systems for Intraperitoneal Therapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Gaurav","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,3]]},"reference":[{"key":"31_CR1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000050149","volume":"18","author":"T Liakakos","year":"2001","unstructured":"Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg. 2001;18:260\u201373.","journal-title":"Dig Surg"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00365520701708626","volume":"43","author":"B Tingstedt","year":"2008","unstructured":"Tingstedt B, Andersson E, Isaksson K, Andersson R. Clinical impact of abdominal adhesions: what is the magnitude of the problem? Scand J Gastroenterol. 2008;43:255\u201361.","journal-title":"Scand J Gastroenterol"},{"key":"31_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/13543780902939151","volume":"18","author":"JM Davies","year":"2009","unstructured":"Davies JM, O\u2019Neil B. Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options. Expert Opin Investig Drugs. 2009;18:913\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"31_CR4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer 2000;88:358\u201363.","journal-title":"Cancer"},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"e5715","DOI":"10.1371\/journal.pone.0005715","volume":"4","author":"E Drecoll","year":"2009","unstructured":"Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE. 2009;4:e5715.","journal-title":"PLoS ONE"},{"key":"31_CR6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.2001.6172","volume":"81","author":"JI Akahira","year":"2001","unstructured":"Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398\u2013403.","journal-title":"Gynecol Oncol"},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/gyno.1996.4550","volume":"64","author":"JP Curtin","year":"1997","unstructured":"Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9\u201312.","journal-title":"Gynecol Oncol"},{"key":"31_CR8","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4612-1194-5","volume-title":"Peritoneal surgery","author":"GS DiZerega","year":"2000","unstructured":"DiZerega GS. Use of adhesion prevention barriers in pelvic reconstructive and gynecologic surgery. In: diZerega GS, editor. Peritoneal surgery. New York: Springer; 2000."},{"key":"31_CR9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejpb.2007.03.027","volume":"68","author":"Y Yeo","year":"2008","unstructured":"Yeo Y, Kohane DS. Polymers in the prevention of peritoneal adhesions. Eur J Pharm Biopharm. 2008;68:57\u201366.","journal-title":"Eur J Pharm Biopharm"},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2007.04.016","volume":"120","author":"Y Yeo","year":"2007","unstructured":"Yeo Y, Adil M, Bellas E, Astashkina A, Chaudhary N, Kohane DS. Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. J Control Release. 2007;120:178\u201385.","journal-title":"J Control Release"},{"key":"31_CR11","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1016\/j.biomaterials.2007.04.033","volume":"28","author":"Y Yeo","year":"2007","unstructured":"Yeo Y, Bellas E, Highley CB, Langer R, Kohane DS. Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. Biomaterials 2007;28:3704\u201313.","journal-title":"Biomaterials"},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med"},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1\u20136.","journal-title":"N Engl J Med"},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"31_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"31_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","volume":"76","author":"A Gadducci","year":"2000","unstructured":"Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000;76:157\u201362.","journal-title":"Gynecol Oncol"},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol"},{"key":"31_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000011980","volume":"56","author":"A Polyzos","year":"1999","unstructured":"Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291\u20136.","journal-title":"Oncology"},{"key":"31_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","volume":"72","author":"MS Yen","year":"2001","unstructured":"Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet. 2001;72:55\u201360.","journal-title":"Int J Gynaecol Obstet"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-7819-7-5","volume":"7","author":"G Glockzin","year":"2009","unstructured":"Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5.","journal-title":"World J Surg Oncol"},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jso.21325","volume":"100","author":"S Gonzalez-Moreno","year":"2009","unstructured":"Gonzalez-Moreno S, Ortega-Perez G, Gonzalez-Bayon L. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol. 2009;100:287\u201392.","journal-title":"J Surg Oncol"},{"key":"31_CR22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jso.21323","volume":"100","author":"A Nissan","year":"2009","unstructured":"Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, and future. J Surg Oncol. 2009;100:335\u201344.","journal-title":"J Surg Oncol"},{"key":"31_CR23","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita Jr VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"31_CR24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00003495-200161080-00003","volume":"61","author":"M Markman","year":"2001","unstructured":"Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001;61:1057\u201365.","journal-title":"Drugs"},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis Jr JL, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10:1485\u201391.","journal-title":"J Clin Oncol"},{"key":"31_CR26","unstructured":"NCI clinical announcement for Intraperitoneal chemotherapy for ovarian cancer http:\/\/ctep.cancer.gov\/highlights\/docs\/clin_annc_010506.pdf ."},{"key":"31_CR27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12094-007-0083-7","volume":"9","author":"AA Poveda","year":"2007","unstructured":"Poveda AA, Salazar RR, del Campo JJM, Mendiola CC, Cassinello JJ, Ojeda BB, et al. Update in the management of ovarian and cervical carcinoma. Clin Transl Oncol. 2007;9:443\u201351.","journal-title":"Clin Transl Oncol"},{"key":"31_CR28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.2600740902","volume":"74","author":"K Hirano","year":"1985","unstructured":"Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci. 1985;74:915\u201321.","journal-title":"J Pharm Sci"},{"key":"31_CR29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)28988-1","volume":"178","author":"G Lukas","year":"1971","unstructured":"Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther. 1971;178:562\u20134.","journal-title":"J Pharmacol Exp Ther"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-003-0680-2","volume":"52","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"31_CR31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-4804(03)00162-8","volume":"113","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. J Surg Res. 2003;113:114\u201320.","journal-title":"J Surg Res"},{"key":"31_CR32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11095-007-9298-0","volume":"24","author":"M Tsai","year":"2007","unstructured":"Tsai M, Lu Z, Wang J, Yeh T-K, Wientjes M, Au J. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res. 2007;24:1691\u2013701.","journal-title":"Pharm Res"},{"key":"31_CR33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.108.140095","volume":"327","author":"Z Lu","year":"2008","unstructured":"Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327:673\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.sla.0000251519.49405.55","volume":"245","author":"Y Yeo","year":"2007","unstructured":"Yeo Y, Ito T, Bellas E, Highley CB, Marini R, Kohane DS. In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg. 2007;245:819\u201324.","journal-title":"Ann Surg"},{"key":"31_CR35","first-page":"1237","volume":"8","author":"H Gelderblom","year":"2002","unstructured":"Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8:1237\u201341.","journal-title":"Clin Cancer Res"},{"key":"31_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s002800050973","volume":"44","author":"I Knemeyer","year":"1999","unstructured":"Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol. 1999;44:241\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"31_CR37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263\u20138.","journal-title":"J Clin Oncol"},{"key":"31_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jbm.a.30654","volume":"77A","author":"DS Kohane","year":"2006","unstructured":"Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Materi Res Part A. 2006;77A:351\u201361.","journal-title":"J Biomed Materi Res Part A"},{"key":"31_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0939-6411(02)00037-1","volume":"54","author":"T Tamura","year":"2002","unstructured":"Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, et al. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm. 2002;54:1\u20137.","journal-title":"Eur J Pharm Biopharm"},{"key":"31_CR40","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1158\/0008-5472.CAN-09-0061","volume":"69","author":"YH Huang","year":"2009","unstructured":"Huang YH, Zugates GT, Peng W, Holtz D, Dunton C, Green JJ, et al. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 2009;69:6184\u201391.","journal-title":"Cancer Res"},{"key":"31_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","volume":"74","author":"D Fukumura","year":"2007","unstructured":"Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74:72\u201384.","journal-title":"Microvasc Res"},{"key":"31_CR42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(00)00131-9","volume":"46","author":"RK Jain","year":"2001","unstructured":"Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149\u201368.","journal-title":"Adv Drug Deliv Rev"},{"key":"31_CR43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0959-8049(05)80025-5","volume":"30","author":"S Bennis","year":"1994","unstructured":"Bennis S, Chapey C, Robert J, Couvreur P. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer. 1994;30:89\u201393.","journal-title":"Eur J Cancer"},{"key":"31_CR44","first-page":"1949","volume":"6","author":"D Goren","year":"2000","unstructured":"Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000;6:1949\u201357.","journal-title":"Clin Cancer Res"},{"key":"31_CR45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1046\/j.1365-2141.1999.01505.x","volume":"106","author":"M Michieli","year":"1999","unstructured":"Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Michelutti T, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol. 1999;106:92\u20139.","journal-title":"Br J Haematol"},{"key":"31_CR46","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/jnci\/84.24.1909","volume":"84","author":"A Rahman","year":"1992","unstructured":"Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992;84:1909\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"31_CR47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1081\/LPR-120016196","volume":"12","author":"D Sadava","year":"2002","unstructured":"Sadava D, Coleman A, Kane SF. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2002;12:301\u20139.","journal-title":"J Liposome Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-0031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-009-0031-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-0031-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T23:17:07Z","timestamp":1739920627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-009-0031-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,3]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s11095-009-0031-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,3]]}}}